Federal Grant to Fund Inhaled Vaccines
A $20.7M federal grant will fund a 5-year inhaled vaccines initiative at the Icahn School of Medicine at Mount Sinai beginning with development of an avian influenza nasal spray prototype.
A $20.7M federal grant will fund a 5-year inhaled vaccines initiative at the Icahn School of Medicine at Mount Sinai beginning with development of an avian influenza nasal spray prototype.
The FDA approved over-the-counter Mucinex 12hr Cold & Fever Multi-Symptom.
Read MoreThe FDA approved Moderna’s mFlusiva, the first seasonal influenza vaccine using mRNA technology to enter the US market.
Read MoreMerck is seeking expand approval for its RSV drug Enflonsia to include children under age two through their second year of risk.
Read MoreA UCLA Health study compared azithromycin and roflumilast in protecting against acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Read MoreOrzeyful is the first drug to target the underlying loss of orexin signaling to address the full range of narcolepsy type 1.
Read MoreIn kidney transplant recipients, early antiviral treatment with remdesivir reduced the risk of organ rejection and heart complications by nearly half for up to one year after diagnosis.
Read MoreZidesamtinib (Jideytro) is approved for patients with ROS1-positive non-small cell lung cancer who have previously received targeted therapy.
Read MoreAstraZeneca’s triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
Read MoreA large-scale study finds that the introduction of asthma biologics in 2015 has led to immediate and sustained reductions in exacerbations at the population level.
Read MoreThe FDA will review a New Drug Application for Apnimed’s AD109, an investigational oral pill for the treatment of adults with obstructive sleep apnea with a target action date of Feb 28, 2027.
Read MoreA phase 1 study is testing the safety of a microneedle device designed to deliver peanut protein through the skin for desensitization.
Read MoreNuvaira treated the first patient treated in a clinical trial evaluating a one-time lung denervation therapy for patients with specific COPD symptoms.
Read MoreGrifols enrolled the first patient in its Phase 3 SWIFT-SC clinical trial to evaluate its subcutaneous Alpha1-Proteinase Inhibitor for the treatment of alpha1-antitrypsin (AAT) deficiency.
Read MoreEnanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Read MoreInsilico Medicine initiated a Phase 3 clinical trial for Rentosertib, an oral medication discovered using artificial intelligence to treat idiopathic pulmonary fibrosis (IPF).
Read MoreThe FDA’s PreCheck Pilot Program will expand domestic pharmaceutical manufacturing, increase production capacity, and strengthen US drug supply chain resilience.
Read More